The immunopathology of ANCA-associated vasculitis

被引:59
|
作者
McKinney, Eoin F. [1 ,2 ,3 ]
Willcocks, Lisa C. [3 ]
Broecker, Verena [4 ]
Smith, Kenneth G. C. [1 ,2 ,3 ]
机构
[1] Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge, England
[2] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England
[3] Addenbrookes Hosp, Vasculitis & Lupus Serv, Cambridge, England
[4] Addenbrookes Hosp, Dept Pathol, Cambridge, England
关键词
ANCA; Vasculitis; Anti-neutrophil cytoplasmic antibody; PR3; MPO; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; T-CELL-ACTIVATION; PRIMARY SYSTEMIC VASCULITIS; SMALL-VESSEL VASCULITIS; WEGENERS-GRANULOMATOSIS; MICROSCOPIC POLYANGIITIS; RHEUMATOID-ARTHRITIS; PROTEINASE-3; PR3; MEMBRANE PROTEINASE-3; COMPLEMENT ACTIVATION;
D O I
10.1007/s00281-014-0436-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The small-vessel vasculitides are a group of disorders characterised by variable patterns of small blood vessel inflammation producing a markedly heterogeneous clinical phenotype. While any vessel in any organ may be involved, distinct but often overlapping sets of clinical features have allowed the description of three subtypes associated with the presence of circulating anti-neutrophil cytoplasmic antibodies (ANCA), namely granulomatosis with polyangiitis (GPA, formerly known as Wegener's Granulomatosis), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (eGPA, formerly known as Churg-Strauss syndrome). Together, these conditions are called the ANCA-associated vasculitidies (AAV). Both formal nomenclature and classification criteria for the syndromes have changed repeatedly since their description over 100 years ago and may conceivably do so again following recent reports showing distinct genetic associations of patients with detectable ANCA of distinct specificities. ANCA are not only useful in classifying the syndromes but substantial evidence implicates them in driving disease pathogenesis although the mechanism by which they develop and tolerance is broken remains controversial. Advances in our understanding of the pathogenesis of the syndromes have been accompanied by some progress in treatment, although much remains to be done to improve the chronic morbidity associated with the immunosuppression required for disease control.
引用
收藏
页码:461 / 478
页数:18
相关论文
共 50 条
  • [41] Biomarkers in ANCA-Associated Vasculitis
    Lindsay Lally
    Robert F. Spiera
    Current Rheumatology Reports, 2013, 15
  • [42] Treatment of ANCA-associated vasculitis
    Ulf Schönermarck
    Wolfgang L. Gross
    Kirsten de Groot
    Nature Reviews Nephrology, 2014, 10 : 25 - 36
  • [43] Spectrum of ANCA-Associated Vasculitis
    Sinha, Aditi
    Bagga, Arvind
    INDIAN JOURNAL OF PEDIATRICS, 2017, 84 (10): : 737 - 738
  • [44] Rituximab in ANCA-Associated Vasculitis
    Romina I. Hassan
    Angelo L. Gaffo
    Current Rheumatology Reports, 2017, 19
  • [45] Rituximab in ANCA-Associated Vasculitis
    Hassan, Romina I.
    Gaffo, Angelo L.
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (02)
  • [46] Pathogenesis of ANCA-associated Vasculitis
    Flint, Julia
    Morgan, Matthew D.
    Savage, Caroline O. S.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 463 - +
  • [47] Updates in ANCA-associated vasculitis
    Ross, Carolyn
    Makhzoum, Jean-Paul
    Pagnoux, Christian
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2022, 9 (03) : 153 - 166
  • [48] Biomarkers in ANCA-Associated Vasculitis
    Lally, Lindsay
    Spiera, Robert F.
    CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (10)
  • [49] ANCA-Associated Vasculitis: An Update
    Almaani, Salem
    Fussner, Lynn A.
    Brodsky, Sergey
    Meara, Alexa S.
    Jayne, David
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
  • [50] The Future of ANCA-associated Vasculitis
    Holle, Julia U.
    Wieczorek, Stefan
    Gross, Wolfgang L.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 609 - +